Prognostic Significance of Serum Proangiogenic Molecules in Patients with De Novo Non-Hodgkin Lymphomas

Overview

Journal ScientificWorldJournal

Publisher Wiley

Specialty Biology

Date 2012 May 26

PMID 22629121

Citations 1

Authors

Pairaya Rujirojindakul

Arnuparp Lekhakula

Affiliations

Soon will be listed here.

Abstract

This study was aimed to assess the clinical significances of the serum VEGF and bFGF in Thai patients with de novo NHL. Serum VEGF and bFGF concentrations were measured from 79 adult patients with newly diagnosed stage 2-4 non-Hodgkin lymphomas by quantitative sandwich enzyme immunoassay. At the time of diagnosis, the serum VEGF concentrations from 79 patients ranged from 72.0 to 2919.4 pg/mL, with a mean of 668.0 pg/dL. The serum bFGF concentrations ranged from undetectable to 2919.4 pg/mL, with a mean of 12.15 pg/dL. Multivariate analysis identified higher than the mean of serum VEGF, B symptoms, bulky diseases, anemia, and treatment with CHOP or R-CHOP as independent variables influencing the complete remission rate. From a Cox proportional hazards model, variables independently associated with overall survival were bone marrow involvement, more extranodal involvement, poor performance status, anemia, and higher than the mean of serum bFGF.

Citing Articles

VEGF overexpression is a valuable prognostic factor for non-Hodgkin's lymphoma evidence from a systemic meta-analysis.

Yang J, Li W, He X, Zhang G, Yue L, Chai Y Dis Markers. 2015; 2015:786790.

PMID: 25810565 PMC: 4355555. DOI: 10.1155/2015/786790.

References

Salven P, Teerenhovi L, Joensuu H . A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood. 1997; 90(8):3167-72. View

Ribatti D, Vacca A, Nico B, Fanelli M, Roncali L, Dammacco F . Angiogenesis spectrum in the stroma of B-cell non-Hodgkin's lymphomas. An immunohistochemical and ultrastructural study. Eur J Haematol. 1996; 56(1-2):45-53. DOI: 10.1111/j.1600-0609.1996.tb00293.x. View

DAmato R, Loughnan M, Flynn E, Folkman J . Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994; 91(9):4082-5. PMC: 43727. DOI: 10.1073/pnas.91.9.4082. View

Crivellato E, Nico B, Vacca A, Ribatti D . B-cell non-Hodgkin's lymphomas express heterogeneous patterns of neovascularization. Haematologica. 2003; 88(6):671-8. View

Hanahan D, Folkman J . Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996; 86(3):353-64. DOI: 10.1016/s0092-8674(00)80108-7. View

Kumar S, Witzig T, Dispenzieri A, Lacy M, Wellik L, Fonseca R . Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. Leukemia. 2004; 18(3):624-7. DOI: 10.1038/sj.leu.2403285. View

Nguyen M, Watanabe H, Budson A, Richie J, Hayes D, Folkman J . Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst. 1994; 86(5):356-61. DOI: 10.1093/jnci/86.5.356. View

Bartlett J, Dredge K, Dalgleish A . The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 2004; 4(4):314-22. DOI: 10.1038/nrc1323. View

Iruela-Arispe M, Dvorak H . Angiogenesis: a dynamic balance of stimulators and inhibitors. Thromb Haemost. 1997; 78(1):672-7. View

10.

Folkman J . Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995; 1(1):27-31. DOI: 10.1038/nm0195-27. View

11.

Tzankov A, Heiss S, Ebner S, Sterlacci W, Schaefer G, Augustin F . Angiogenesis in nodal B cell lymphomas: a high throughput study. J Clin Pathol. 2006; 60(5):476-82. PMC: 1994554. DOI: 10.1136/jcp.2006.038661. View

12.

Brunner G, Nguyen H, Gabrilove J, Rifkin D, Wilson E . Basic fibroblast growth factor expression in human bone marrow and peripheral blood cells. Blood. 1993; 81(3):631-8. View

13.

Salven P, Orpana A, Teerenhovi L, Joensuu H . Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. Blood. 2000; 96(12):3712-8. View

14.

Salven P, Teerenhovi L, Joensuu H . A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma. Blood. 1999; 94(10):3334-9. View

15.

Medinger M, Fischer N, Tzankov A . Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies. J Oncol. 2010; 2010:729725. PMC: 2875768. DOI: 10.1155/2010/729725. View

16.

Ganjoo K, Moore A, Orazi A, Sen J, Johnson C, An C . The importance of angiogenesis markers in the outcome of patients with diffuse large B cell lymphoma: a retrospective study of 97 patients. J Cancer Res Clin Oncol. 2007; 134(3):381-7. DOI: 10.1007/s00432-007-0294-x. View

17.

Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F . Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol. 1994; 87(3):503-8. DOI: 10.1111/j.1365-2141.1994.tb08304.x. View

18.

Vacca A, Ribatti D, Presta M, Minischetti M, Iurlaro M, Ria R . Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood. 1999; 93(9):3064-73. View

19.

Bertolini F, Paolucci M, Peccatori F, Cinieri S, Agazzi A, Ferrucci P . Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. Br J Haematol. 1999; 106(2):504-9. DOI: 10.1046/j.1365-2141.1999.01547.x. View

20.

Mangi M, Newland A . Angiogenesis and angiogenic mediators in haematological malignancies. Br J Haematol. 2000; 111(1):43-51. DOI: 10.1046/j.1365-2141.2000.02104.x. View